Established clinical, pathologic features and biomarkers such as patient age, tumor size, nodal status, tumor grade, ER, progesterone receptor (PR), and HER2 status are used to estimate a patient’s risk for recurrence and to guide treatment options. The gene discussed is ESR1; the disease is neoplasm.